917 results match your criteria: "U1068; Aix-Marseille Universite[Affiliation]"
Curr Oncol
March 2022
Department of Early Phase Cancer Trials Center «CLIP2», CHU Timone, Assistance Publique Hôpitaux de Marseille, Aix-Marseille University, 13005 Marseille, France.
Background: Cancer therapies targeting actionable molecular alterations (AMA) have developed, but the clinical routine impact of high-throughput molecular profiling remains unclear. We present a monocentric experience of molecular profiling based on liquid biopsy in patients with cancer.
Methods: Patients included had solid cancer and underwent cfDNA genomic profiling with FoudationOne Liquid CDx (F1LCDx) test, analyzing 324 genes.
Oncologist
June 2022
Department of Medical Oncology, Strasbourg-Europe Cancer Institute (ICANS), Strasbourg, France.
Background: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are aggressive neoplasms. Data linking BAF alterations with tumor microenvironment (TME) and efficacy of immune checkpoint inhibitors (ICI) are contradictory. The TME of SMARCA4-UT and their response to ICI are unknown.
View Article and Find Full Text PDFCancer Immunol Res
May 2022
Department of Structural Biology, Stanford University School of Medicine, Stanford, California.
γδ T cells stimulated by phosphoantigens (pAg) are potent effectors that secrete Th1 cytokines and kill tumor cells. Consequently, they are considered candidates for use in cancer immunotherapy. However, they have proven only moderately effective in several clinical trials.
View Article and Find Full Text PDFFront Oncol
February 2022
Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), Section of Medical Oncology, University of Palermo, Palermo, Italy.
Front Cell Infect Microbiol
April 2022
Clinical Research and R&D Department, Laboratoire Européen Alphabio, Marseille, France.
Microbiotas play critical roles in human health, yet in most cases scientists lack standardized and reproducible methods from collection and preservation of samples, as well as the choice of omic analysis, up to the data processing. To date, stool sample preservation remains a source of technological bias in metagenomic sequencing, despite newly developed storage solutions. Here, we conducted a comparative study of 10 storage methods for human stool over a 14-day period of storage at fluctuating temperatures.
View Article and Find Full Text PDFCancers (Basel)
February 2022
Laboratory of Predictive Oncology, Cancer Research Center of Marseille, Inserm U1068-CNRS UMR7258-Université Aix-Marseille UM105, Label "Ligue Contre le Cancer", 13009 Marseille, France.
Circulating tumor cells have a strong potential as a quasi-non-invasive tool for setting up a precision medicine strategy for cancer patients. Using a second-generation "filtration-based" technology to isolate CTCs, the Screencell™ technology (Sarcelles, France), we performed a large and simultaneous analysis of all atypical circulating tumor cells () isolated from the blood of metastatic breast cancer (mBC) patients. We correlated their presence with clinicopathological and survival data.
View Article and Find Full Text PDFDiagnostics (Basel)
January 2022
General Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56124 Pisa, Italy.
In recent years, a growing number of studies have evaluated the role of exosomes in pancreatic ductal adenocarcinoma cancer (PDAC) demonstrating their involvement in a multitude of pathways, including the induction of chemoresistance. The aim of this review is to present an overview of the current knowledge on the role of exosomes in the resistance to gemcitabine and nab-paclitaxel, which are two of the most commonly used drugs for the treatment of PDAC patients. Exosomes are vesicular cargos that transport multiple miRNAs, mRNAs and proteins from one cell to another cell and some of these factors can influence specific determinants of gemcitabine activity, such as the nucleoside transporter hENT1, or multidrug resistance proteins involved in the resistance to paclitaxel.
View Article and Find Full Text PDFEMBO J
March 2022
Marseille Cancer Research Center (CRCM), U1068 Inserm, UMR7258 CNRS, Institut Paoli-Calmettes, Equipe labellisée Ligue, Aix Marseille University, Marseille, France.
As in human cells, yeast telomeres can be maintained in cells lacking telomerase activity by recombination-based mechanisms known as ALT (Alternative Lengthening of Telomeres). A hallmark of ALT human cancer cells are extrachromosomal telomeric DNA elements called C-circles, whose origin and function have remained unclear. Here, we show that extrachromosomal telomeric C-circles in yeast can be detected shortly after senescence crisis and concomitantly with the production of survivors arising from "type II" recombination events.
View Article and Find Full Text PDFCancer Chemother Pharmacol
April 2022
COMPO Unit, Centre de Recherche en Cancérologie de Marseille, Inserm U1068 Inria Centre de Recherches Sophia Méditerranée, Aix Marseille Université, 13385, Marseille, France.
Purpose: Adaptive dosing strategy with oral targeted therapies in oncology is mostly based upon clinical signs. Using pharmacokinetics (PK) models to customize dosing could help saving time, i.e.
View Article and Find Full Text PDFBull Cancer
February 2022
Institut Paoli-Calmettes, université Aix-Marseille, département d'oncologie médicale, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France; CRCM-laboratoire d'oncologie prédictive, Inserm U1068, CNRS UMR7258, institut Paoli-Calmettes, université Aix-Marseille, 13009 Marseille, France.
Overall, 2021 was marked by the confirmation of the major interest of cell cycle inhibitors for hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative advanced breast cancers with very high overall survival data exceeding five years for hormone-sensitive disease. Studies have also confirmed the efficacy and safety of this therapeutic class in the elderly population. New cell cycle inhibitors are under development (SHR6390).
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
May 2022
French Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades University Hospital, APHP, Paris, France; Paris University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University Hospital, Paris, France. Electronic address:
Background: Mast cells are key players in innate immunity and the T2 adaptive immune response. The latter counterbalances the T1 response, which is critical for antiviral immunity. Clonal mast cell activation disorders (cMCADs, such as mastocytosis and clonal mast cell activation syndrome) are characterized by abnormal mast cell accumulation and/or activation.
View Article and Find Full Text PDFJ Clin Med
January 2022
Unité Parasitologie et Entomologie, Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, 91220 Marseille, France.
SARS-CoV-2 has caused a large outbreak since its emergence in December 2019. COVID-19 diagnosis became a priority so as to isolate and treat infected individuals in order to break the contamination chain. Currently, the reference test for COVID-19 diagnosis is the molecular detection (RT-qPCR) of the virus from nasopharyngeal swab (NPS) samples.
View Article and Find Full Text PDFCancers (Basel)
January 2022
Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
Medulloblastoma patients receive adapted therapies stratified according to their risk-profile. Favourable, standard, and high disease-risk groups are each defined by the status of clinical and pathological risk factors, alongside an evolving repertoire of diagnostic and prognostic biomarkers. Medulloblastoma clinical trials in Europe are coordinated by the International Society for Paediatric Oncology (SIOP-Europe) brain tumour group.
View Article and Find Full Text PDFBlood
April 2022
Laboratory of Genome Dynamics in the Immune System, Laboratoire labellisé Ligue Naionale contre le Cancer, INSERM UMR 1163, Université de Paris, Imagine Institute, Paris, France.
Neurooncol Adv
November 2021
Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.
Background: Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood brainstem tumor for which radiation is the only treatment. Case studies report a clinical response to ONC201 for patients with H3K27M-mutant gliomas. Oncoceutics (ONC201) is only available in the United States and Japan; however, in Germany, DIPG patients can be prescribed and dispensed a locally produced compound-ONC201 German-sourced ONC201 (GsONC201).
View Article and Find Full Text PDFFront Immunol
February 2022
Medical Oncology Department, Paoli-Calmettes Institute, Aix-Marseille University, Marseille, France.
Immune checkpoint inhibitors (ICI) reinvigorate the immune system to recognize and destroy tumor cells. Because of this biological mechanism, patients might develop autoimmune toxicities, notably in the digestive tract (most frequently, hepatitis or colitis). A 70-year-old man with relapsed mesothelioma was treated with nivolumab in 3rd line.
View Article and Find Full Text PDFCancer Radiother
February 2022
Département de d'oncologie radiothérapie, centre Henri-Becquerel, 1, rue d'Amiens, 76000 Rouen, France; QuantIf Litis EA4108, université de Rouen, 76000 Rouen, France.
We present an update of the French society of oncological radiotherapy recommendation regarding indication, doses, and technique of radiotherapy for intrathoracic metastases. The recommendations for delineation of the target volumes and critical organs are detailed.
View Article and Find Full Text PDFCancers (Basel)
December 2021
Faculty of Medicine and Biomedical Sciences (FMCB), Campus de Gambelas, University of Algarve, 8005-139 Faro, Portugal.
Pancreatic cancer (PCA) is one of the most lethal malignancies worldwide with a 5-year survival rate of 9%. Despite the advances in the field, the need for an earlier detection and effective therapies is paramount. PCA high heterogeneity suggests that epigenetic alterations play a key role in tumour development.
View Article and Find Full Text PDFNucleic Acids Res
January 2022
Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA.
The production of ribosomes is an energy-intensive process owing to the intricacy of these massive macromolecular machines. Each human ribosome contains 80 ribosomal proteins and four non-coding RNAs. Accurate assembly requires precise regulation of protein and RNA subunits.
View Article and Find Full Text PDFCell Mol Immunol
February 2022
Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068; CNRS, UMR7258; Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
Cancers (Basel)
December 2021
Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine, Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Ramiro de Maeztu 9, E-28040 Madrid, Spain.
Pancreatic cancer is one of the most lethal malignancies with a poor and gloomy prognosis and the highest mortality-to-incidence ratio. Pancreatic cancer remains an incurable malignancy, and current therapies are ineffective. We isolated cancer stem cells (CSCs) from the human PANC-1 pancreatic cancer cell line as CD44CD24EpCAM cells.
View Article and Find Full Text PDFCancer Discov
March 2022
Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Unlabelled: Cancer cell metabolism is increasingly recognized as providing an exciting therapeutic opportunity. However, a drug that directly couples targeting of a metabolic dependency with the induction of cell death in cancer cells has largely remained elusive. Here we report that the drug-like small-molecule ironomycin reduces the mitochondrial iron load, resulting in the potent disruption of mitochondrial metabolism.
View Article and Find Full Text PDFAm J Surg Pathol
June 2022
Pathology and Tumor Immunology, Institut Paoli-Calmettes, Research Center in Cancer of Marseille, INSERM U1068, CNRS UMR7258, Aix-Marseille University, UM105.
Despite the impressive efficacy of chimeric antigen receptor (CAR) T-cell therapy (CART) in B-cell non-Hodgkin lymphomas, durable responses are uncommon. The histopathologic and molecular features associated with treatment failure are still largely unknown. Therefore, we have analyzed 19 sequential tumor samples from 9 patients, prior anti-CD19 CART (pre-CART) and at relapse (post-CART), using immunohistochemistry, fluorescence in situ hybridization, array comparative genomic hybridization, next-generation DNA and RNA sequencing, and genome-scale DNA methylation.
View Article and Find Full Text PDFEur J Cancer
December 2021
Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France. Electronic address:
Background: Hormone-resistant HER2-negative or triple-negative advanced breast cancers (ABC) are routinely treated with paclitaxel chemotherapy. LY2780301 is a dual inhibitor of p70 ribosomal protein S6 kinase and AKT. The TAKTIC study aimed at exploring the combination of paclitaxel and LY2780301 in this population.
View Article and Find Full Text PDFAm J Respir Crit Care Med
January 2022
Sorbonne Université-Institut National de la Santé et de la Recherche Médicale-Centre National de la Recherche Scientifique, Centre d'Immunologie et des Maladies Infectieuses, Paris, France.
Sepsis is the leading cause of death in adult ICUs. At present, sepsis diagnosis relies on nonspecific clinical features. It could transform clinical care to have immune-cell biomarkers that could predict sepsis diagnosis and guide treatment.
View Article and Find Full Text PDF